A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

912

Participants

Timeline

Start Date

December 4, 2012

Primary Completion Date

May 13, 2015

Study Completion Date

July 30, 2015

Conditions
Endometriosis
Interventions
DRUG

ASP1707

Oral

DRUG

Placebo

Oral

DRUG

Leuprorelin acetate

subcutaneous

Trial Locations (85)

1000

Site: 1104, Sofia

1135

Site: 1401, Budapest

1200

Site: 1006, Brussels

1330

Site: 1107, Sofia

1504

Site: 1106, Sofia

3000

Site: 1001, Leuven

3600

Site: 1002, Genk

4000

Site: 1005, Liège

4012

Site: 1408, Debrecen

6000

Site: 1103, Stara Zagora

Site: 1422, Kecskemét

7100

Site: 1403, Szekszárd

9000

Site: 1003, Ghent

11475

Site: 1602, Bucharest

1130033

Site: 2003, Tokyo

Unknown

Site: 1105, Plovdiv

Site: 1102, Sofia

Site: 1390, Berlin

Site: 1304, Dresden

Site: 1302, Erlangen

Site: 1311, Karlsruhe

Site: 1306, Lübeck

Site: 1407, Budapest

Site: 1406, Pécs

Site: 1402, Székesfehérvár

Site: 2039, Hyōgo

Site: 2040, Hyōgo

Site: 2032, Kagoshima

Site: 2035, Kanagawa

Site: 2036, Nagano

Site: 2037, Nagano

Site: 2038, Nagano

Site: 2016, Tokyo

Site: 1505, Bialystok

Site: 1512, Gdansk

Site: 1509, Warsaw

Site: 1525, Warzawa

Site: 1604, Brasov

Site: 1607, Bucaresti

Site: 1601, Bucharest

Site: 1606, Bucharest

Site: 1603, Târgu Mureş

Site: 1701, Bucuresti

Site: 1702, Bucuresti

Site: 1705, Bucuresti

Site: 1707, Bucuresti

Site: 1713, Donetsk

Site: 1716, Donetsk

Site: 1708, Kyiv

Site: 1703, Targu Mures

Site: 1717, Zaporizhzhya

036 8203

Site: 2018, Aomori

299 0111

Site: 2017, Chiba

252 0804

Site: 2005, Fujisawa

666 0195

Site: 2034, Hyōgo

213 8507

Site: 2015, Kanagawa

350-8550

Site: 2013, Kawagoe

210 0024

Site: 2029, Kawasaki

212 0058

Site: 2024, Kawasaki

783 8505

Site: 2033, Kochi

861 8520

Site: 2031, Kumamoto

710 0824

Site: 2010, Kurashiki

602 8566

Site: 2006, Kyoto

940 2085

Site: 2002, Nagaoka

850 0003

Site: 2007, Nagasaki

631 0805

Site: 2011, Nara

060 0001

Site: 2027, Sapporo

060 0031

Site: 2001, Sapporo

060 0061

Site: 2030, Sapporo

101 0062

Site: 2004, Tokyo

107 0052

Site: 2020, Tokyo

113 8431

Site: 2014, Tokyo

113 8603

Site: 2009, Tokyo

141 0022

Site: 2028, Tokyo

157 0061

Site: 2025, Tokyo

225 0024

Site: 2012, Yokohama

15-464

Site: 1501, Bialystok

40-724

Site: 1504, Katowice

20-333

Site: 1508, Lublin

20-632

Site: 1507, Lublin

02-066

Site: 1502, Warsaw

SE5 9RS

Site: 1807, London

NR47UY

Site: 1804, Norwich

S10 2SF

Site: 1808, Sheffield

SO16 5YA

Site: 1806, Southampton

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01767090 - A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain | Biotech Hunter | Biotech Hunter